Motso et al. reasoned that novel β2AR agonists that efficaciously stimulate glucose uptake while only weakly activating the Gs/cAMP/PKA signaling axis could serve as potential drug candidates to treat type 2 diabetes and obesity. The gene discussed is ADRB2; the disease is obesity due to melanocortin 4 receptor deficiency.